Document is current

Article History

Received: 14 December 2023

Accepted: 10 June 2024

First Online: 17 June 2024

Declarations

:

: The main STIC-AVASTIN trial was a French multicenter, non-comparative study (NCT00489697, ID number INCA06-FT/STIC-AVASTIN). This study was approved by Tours Ethics Committee (2006-R10) and the Institutional Review Board. No additional approval was required for the post hoc analysis.

: Not applicable.

: TM received honoraria for speaking or consulting roles from Servier, Pierre Fabre, Merck Serono, AAA, Sanofi, Galapagos, and research grants from Amgen and Roche. He also received travel grants from Pierre Fabre, Merck Serono, and Sanofi. OB received honoraria for speaking or consulting roles from Apmonia Therapeutics, Merck KGaA, Bayer, MSD, Amgen, Deciphera, Servier, and Pierre Fabre, outside the submitted work. TL received honoraria for speaking or for consulting roles from Servier, Pierre Fabre, Merck Serono, BMS, Astra Zeneca, AAA, Sanofi, IPSEN, Novartis, CHUGAI outside the submitted work; research grants from Pierre Fabre and Leo Pharma outside the submitted work; and travel grants from IPSEN, Merck Serono, AMGEN, Astra Zeneca, Pierre Fabre and Servier outside the submitted work. EA received honoraria for speaking or consulting roles from Roche, Novartis, MSD, Astra Zeneca, Bayer, Ipsen, Boston, Incyte, Servier, AAA. CM, EML, JL, RC, CB, PAD, and AB declare no competing interests.